Le Lézard
Classified in: Science and technology
Subjects: CCA, DIS, FVT, DEI

AudioEye Sets First Quarter 2024 Earnings Call


TUCSON, Ariz., April 8, 2024 /PRNewswire/ -- AudioEye, Inc. (Nasdaq: AEYE) ("AudioEye" or the "Company"), the industry-leading enterprise SaaS accessibility company, will hold a conference call on Tuesday, April 23, 2024 at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter ended March 31, 2024. Financial results will be issued in a press release prior to the call.

AudioEye management will host the conference call, followed by a question and answer period.

Date: Tuesday, April 23, 2024
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
U.S. dial-in number: 888-348-8931
International number: 412-317-0453
Webcast: Q124 Webcast Link

Please call the conference telephone number 5-10 minutes prior to the start time. If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

The conference call will also be webcast live and available for replay via the investor relations section of the Company's website. The audio recording will remain available via the investor relations section of the Company's website for 90 days.

A telephonic replay of the conference call will also be available after 7:30 p.m. Eastern Time on the same day through May 7, 2024 via the following numbers:

Toll-free replay number: 844-512-2921
International replay number: 412-317-6671
Replay passcode: 10187106

About AudioEye
AudioEye exists to ensure the digital future we build is inclusive. By combining the latest AI automation technology with guidance from certified experts and direct input from the disability community, AudioEye helps ensure businesses of all sizes ? including over 110,000 customers like Samsung, Calvin Klein, and Samsonite ? are accessible and usable. Holding 22 US patents, AudioEye helps companies solve every aspect of digital accessibility with flexible approaches that best meet their needs ? from finding and removing barriers to navigating legal compliance, to ongoing training, monitoring and upkeep. Join AudioEye on its mission to eradicate barriers to digital access.

Investor Contact:
Tom Colton or Luke Johnson
Gateway Group, Inc.
[email protected]
949-574-3860

SOURCE AudioEye, Inc.


These press releases may also interest you

at 02:34
Elbit Systems Awarded $37 Million Contract to Supply Iron Fist APS for Upgrading U.S. Army's Bradley IFVs
Elbit Systems Ltd.  ("Elbit Systems" or the "Company") announced today that it was awarded an initial contract of approximately $37 million to supply Iron Fist Active Protection Systems (APS) to General Dynamics Ordnance and Tactical Systems...

4 mai 2024
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
U.S.-based Iozera announces MOU with Government of Morocco for Launch of Eco-Friendly AI Data Center in Morocco
U.S.-based tech startup Iozera, in collaboration with the Government of Morocco, announces an initiative set to transform the AI industry. Iozera has announced the signing of a Memorandum of Understanding (MOU) for the establishment of a pioneering...

4 mai 2024
Flash News: OK Wallet Now Integrated with JUICE, a Permissionless DeFi Protocol Built on the Blast Ecosystem's Layer 2 Infrastructure
OKX, a leading Web3 technology company, has issued updates for May 3, 2024. OKX today announced that its Web3 Wallet is now...

4 mai 2024
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
Quick understanding of JA Solar's 2023 annual report
With a remarkable achievement of 81.556 billion yuan in operating revenue, marking an 11.74% increase from the previous year, and a net profit attributable to shareholders of 7.039 billion yuan, soaring by 27.21%, JA Solar hit historic highs in both...

More news about Science and technology...


News published on and distributed by: